Nextgen Biotech

Call us:

Fulviglen 250mg - Fulvestrant Injection

Fulviglen 250mg is a prescription medication used in hormone receptor-positive advanced breast cancer. It works by blocking and degrading estrogen receptors in cancer cells, slowing disease progression in postmenopausal women.

Select your size:

Choose Quantity:

-
+
Share
General Information:
Generic Name: Fulvestrant
Brand Name: Fulviglen
Packing: Single-dose pre-filled syringe or vial
Strength: 250mg/5ml
Manufacturer: Glenmark Pharmaceuticals
Form: Injection
Category: Hormonal Therapy / Selective Estrogen Receptor Degrader (SERD)
Product Intro:
Fulviglen 250mg Injection is a hormone therapy drug primarily used in postmenopausal women for advanced or metastatic breast cancer. It is classified as an estrogen receptor antagonist and degrader, administered via intramuscular injection by a healthcare professional.

Uses:
Fulviglen is indicated for the treatment of:
  1. Hormone receptor-positive metastatic breast cancer
  2. Advanced breast cancer in postmenopausal women
  3. Disease progression following anti-estrogen therapy (e.g., Tamoxifen)
  4. HER2-negative breast cancer in endocrine therapy combinations
  5. Combination with CDK4/6 inhibitors such as Palbociclib
  6. Maintenance therapy in advanced hormone-responsive breast cancer

Storage Instructions:
  1. Store at 2°C to 8°C in a refrigerator
  2. Do not freeze
  3. Protect from direct sunlight and moisture
  4. Keep out of reach of children
  5. Warm to room temperature before injection

How it Works (Mechanism of Action):
Fulvestrant acts as a Selective Estrogen Receptor Degrader (SERD). It binds competitively to estrogen receptors on cancer cells, blocking estrogen action and accelerating receptor degradation, thereby suppressing the growth of estrogen-dependent tumors.

Side Effects:
Common Side Effects:
  1. Hot flashes
  2. Fatigue
  3. Joint or muscle pain
  4. Headache
  5. Injection site pain or swelling
  6. Nausea
Severe Side Effects:
  1. Liver enzyme abnormalities
  2. Blood clots
  3. Vaginal bleeding
  4. Hypersensitivity reactions (rash, anaphylaxis)

Dosage (Typical Recommended Dose):
  1. Initial Dose: 500 mg IM on Days 1, 15, and 29
  2. Maintenance Dose: 500 mg IM every 28 days thereafter
  3. Administered as two 5 ml injections (one in each buttock)

Method of Administration:
  1. Intramuscular (IM) injection in the gluteal muscle
  2. Administered only by trained healthcare professionals
  3. Injection sites should be alternated to minimize discomfort

Precautions:
  1. Contraindicated in pregnant or breastfeeding women
  2. Use cautiously in patients with hepatic impairment
  3. Monitor liver function regularly
  4. Caution in individuals with a history of thromboembolism
  5. Effective contraception is necessary during and after treatment

Drug Interactions:
  1. Few known interactions, but caution with:
    1. Anticoagulants (e.g., warfarin)
    2. Hormonal agents
  2. Always inform your physician of all medications and supplements

Allergies:
  1. Do not use if allergic to Fulvestrant or any of its components
  2. Signs of allergic reaction: swelling, rash, dizziness, breathing difficulty
  3. Immediate medical help should be sought in case of allergic symptoms

Overdose Information:
  1. Overdose is rare due to administration by professionals
  2. Symptoms may include severe nausea, dizziness, or liver abnormalities
  3. Seek immediate emergency assistance if overdose is suspected

Missed Dose Instructions:
  1. Contact your doctor to reschedule a missed injection
  2. Do not self-administer or double the next dose
  3. Continue the treatment cycle as per physician’s direction

Additional Notes:
  1. Fulviglen may be used alone or in combination therapy
  2. Regular monitoring through scans and blood tests is recommended
  3. It does not cure breast cancer but helps in disease control and quality of life improvement
View More

In The Same Category

Cart